Rising Biosciences (Rising Biosciences) Issuance of Debt : $0.00 Mil (TTM As of . 20)

View and export this data going back to . Start your Free Trial

What is Rising Biosciences Issuance of Debt?

Rising Biosciences's Issuance of Debt for the three months ended in . 20 was $0.00 Mil.

Rising Biosciences's Issuance of Debt for the trailing twelve months (TTM) ended in . 20 was $0.00 Mil.

Rising Biosciences Issuance of Debt Historical Data

The historical data trend for Rising Biosciences's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rising Biosciences Issuance of Debt Chart

Rising Biosciences Annual Data

Trend

Issuance of Debt

Rising Biosciences Quarterly Data

Issuance of Debt

Rising Biosciences Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in . 20 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Rising Biosciences Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Rising Biosciences's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Rising Biosciences (Rising Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » Issuance of Debt

Traded in Other Exchanges

N/A

Address

1180 Cleveland Road, Sandusky, OH, USA, 44870

Website

http://www.risingbiosciences.com

Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.